IBRX (US) share price forecast & AI signal — ImmunityBio, Inc
Week of 2026-10-30 · Healthcare
Exact confidence, 1-week / 1-month / 3-month breakdown, plain-English AI write-up, bull-vs-bear debate, support & resistance.
Get 5 free tokens — no card Already a member? Open the full analysisWhat the model sees in IBRX
ImmunityBio, Inc is a Healthcare stock listed on the US. For the week of 2026-10-30 the ACE machine-learning model rates it a BUY with moderate confidence, based on technical indicators and the stock's own historical patterns across three time horizons. The direction is updated every model run.
About ImmunityBio, Inc
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG)...
Recent closes
| Date | Close |
|---|---|
| 2026-11-06 | $8.63 |
| 2026-11-05 | $8.01 |
| 2026-11-04 | $8.93 |
| 2026-11-03 | $8.29 |
| 2026-11-02 | $7.95 |
| 2026-10-30 | $8.29 |
| 2026-10-29 | $8.74 |
IBRX FAQ
Is ImmunityBio, Inc (IBRX) a buy or sell this week?
The ACE Stock Bots machine-learning model rates IBRX a BUY for the week of 2026-10-30 with moderate confidence. The exact confidence and the 1-week, 1-month and 3-month breakdown are free with a signup (5 analysis tokens, no card).
What is the AI share price forecast for IBRX?
Every week the model scores IBRX across three horizons using technical indicators and the stock's own historical patterns. An AI then writes a plain-English summary with support and resistance levels, and a bull analyst and a bear analyst argue the case.
Is this financial advice?
No. ACE Stock Bots provides general information generated by software. It does not consider your objectives, financial situation or needs. Read the disclaimer and consider licensed advice before acting.
Other Healthcare stocks on the US
This week's top US picks · All US stocks
Signals are generated by software for general information only and are not a recommendation to buy or sell. See the disclaimer.